<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03621241</url>
  </required_header>
  <id_info>
    <org_study_id>PI2018_843_0010</org_study_id>
    <nct_id>NCT03621241</nct_id>
  </id_info>
  <brief_title>MODIFY (Mds DIagnosis Flow cYtometry)</brief_title>
  <acronym>MODIFY</acronym>
  <official_title>Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies
      characterized by cytopenia(s), dysplasia in one or more major myeloid cell lines and
      progression to acute leukemia. Morphological analysis of peripheral blood (PB) and bone
      marrow (BM) remains the cornerstone of the diagnosis. Preliminary studies identified Flow
      Cytometry (FC) markers on red cells, platelets and circulating leukocytes that are expressed
      differently in MDS and in controls. However, these markers have been evaluated separately.
      The investigators propose to test in a large cohort of patients these markers, and to combine
      the most relevant ones in order to define a PB FC-based diagnosis score that would
      discriminate between MDS and non-clonal hematopoiesis and would avoid useless bone marrow
      samples in elderly
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Anticipated">June 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>identification of the most relevant combination of FC markers</measure>
    <time_frame>0 days</time_frame>
    <description>The main objective is to identify the most relevant combination of FC markers to discriminate between already diagnosed MDS patients and non-MDS patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prospective validation of a diagnostic score using pre-identified markers</measure>
    <time_frame>0 days</time_frame>
    <description>The secondary objective is to build prospectively a diagnostic score using markers identified</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Flow cytometry</intervention_name>
    <description>Flow cytometry</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        MDS
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient who have been orally informed, and given a short written information notice
             about the study

          2. Adult patient&gt;18 years

          3. For whom a blood sample analysis is routinely prescribed

          4. Presenting cytopenia on at least one lineage according to the 2016 WHO classification
             (Hemoglobin level&lt;100 g/L and/or platelets &lt;150 G/L and/or Neutrophils&lt;1G/L).

          5. For whom a bone marrow analysis for morphology assessment and cytogenetics have to be
             performed, because of suspicion of MDS.t The results of this bone marrow evaluation
             will classify the patients in Group 1 (MDS diagnosis) and Group 2 (no MDS according to
             the 2016 WHO criteria), defining the two populations of this validation cohort for
             whom the FC score will be calculated.

        Exclusion Criteria:

        1. Transfused patients (less than 3 months) in RBC or platelets units
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Loïc Garçon, PD</last_name>
    <phone>33 3 22 08 70 56</phone>
    <email>garcon.loic@chu-amiens.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annabelle Boussault</last_name>
    <email>boussault.annabelle@chu-amiens.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc Garcon</last_name>
      <phone>03 22 08 70 56</phone>
      <email>garcon.loic@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Boyer, MD</last_name>
      <phone>33 320444783</phone>
      <email>THOMAS.BOYER@CHRU-LILLE.FR</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard Lenormand</last_name>
      <phone>333 2 32 88 13 20</phone>
      <email>bernard.lenormand@chu-rouen.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <last_update_submitted>April 5, 2019</last_update_submitted>
  <last_update_submitted_qc>April 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

